Older patients with acute myeloid leukemia are traditionally treated with intensive induction chemotherapy and derive benefit, but responses are not durable, and the overall survival (OS) with this treatment in short. It was hypothesized by Guillermo Garcia-Manero, MD et al, that maintenance therapy for post-remission AML might improve upon survival in the patient population, and the phase 3 QUAZAR AML-001 clinical trial was designed to investigate the hypothesis.
The oral hypomethylating agent, CC-486 induced a statistically significant improvement in OS compared with placebo in patients with AML, according to results from QUAZAR AML-001 (NCT0175753). These study findings recently drove the FDAs decision to approve the drug as a maintenance treatment for adult patients with AML who achieved a first complete remission or with incomplete blood count recovery after intensive induction chemotherapy and who are unable to complete intensive curative therapy.
The OS observed with CC-486 in QUAZAR AML-001 was 24.7 months compared with 14.8 months with placebo (HR, 0.69; 95% CI, 0.55-0.86;P=.0009). In addition to the OS benefit, relapse-free survival (RFS) was improved with CC-486 at 10.2 months compared to only 4.8 months with placebo(HR, 0.65; 95% CI, 0.52-0.81;P=.0001). During the presentation of these findings at the 2019 American Society of Hematology (ASH) Annual Meeting, the investigators concluded that CC-482 is the first agent used in the maintenance setting to show statistically significant and clinically meaningful improvements in both OS and RFS in post-remission patients with AML.
In an interview with Targeted Oncology following the FDA approval of CC-486, Dr. Garcia-Manero, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission AML.
TARGETED ONCOLOGY: It is known that azacitidine injection is effective for the treatment of AML, but why was is necessary to develop a new form of this drug?
Garcia-Manero: We refer to these drugs as hypomethylating agents. The issue with them is that if the patient responds to them, this requires therapy that could last for multiple months or years. We have 2 hypomethylating agents now, which are decitabine and azacitidine. The agents are usually given for five days a month or sometimes seven consecutive days a month.
This means some patients have to take IV or subcutaneous injections every week for the rest of their life.Because of this, weve been trying to develop an oral hypomethylating agent for about 50 years, and its exciting that we finally have it.
TARGETED ONCOLOGY: What was the rationale for the QUAZAR AML-001 clinical trial?
Garcia-Manero: This was a very interesting study where patients with AML that were in remission were treated in a randomized fashion with azacitadine tablets or a control. The problem with AML is relapse and there have been multiple trying this concept of maintenance therapies to see if some type of low-dose intensive chemotherapy approach would improve survival.
TARGETED ONCOLOGY: What were the key findings of the QUAZAR AML-001 study? What was the safety profile observed with CC-486 in this study?
Garcia-Manero: This is the first study where we see a survival benefit that is quite significant with the hypomethylating agent CC-486, which is a consolidation therapy approach rather than doing nothing.
The data are highly significant in terms of improvement in OS. It is close to 10 months which we have not seen in the past with almost no intervention. The only intervention performed was stem cell transplantation.
The toxicity profile of the compound was well tolerated. That said, these kinds of drugs are mild forms of chemotherapy and therefore can induce cytopenia or mild gastrointestinal toxicities.
TARGETED ONCOLOGY: Now that CC-486 is FDA approved, what will be the overall impact of this drug in the AML treatment landscape?
Garcia-Manero: Theres an interesting shift in the landscape because another oral hypomethylating agent (decitabine) was approved by the FDA last month. For CC-486, in particular, I think were going to have to decide what the role of the drug is outside its current indication of post-consolidation maintenance therapy because this CC-486 is not exactly like azacitadine, it has a different pharmacokinetic and pharmacodynamic profile. We are going to have to design new studies in AML and myelodysplastic syndrome. Right now, the role of CC-486 is clearly post-consolidation maintenance therapy.
TARGETED ONCOLOGY: How would you advise oncologists to use CC-486 in practice, now that is available?
Garcia-Manero: In my opinion, using for CC-486 in patients that have completed consolidation therapy, or who are not candidates for stem cell transplantation or had significant toxicity from consolidation, the data from QUAZAR constitute using CC-486 as the standard of care. I would advise using this maintenance approach for this patient population.
If a patient can undergo stem cell transplantation, that should be considered over CC-486. I think the future, we should also pay attention to particular genetic alterations of the patients because there may be a specific subset of patient mutated disease that may be candidates for other targeted agents instead of CC-486.
Reference:
Wei A,DohnerH, Pocock C, et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation ofAzacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission.Blood.2019;134(suppl 2):LBA3.doi:10.1182/blood-2019-132405.
Excerpt from:
CC-486 Constitutes Standard of Care for Subset of Patients with AML - Targeted Oncology
- Using stem cell-derived heart muscle cells to advance heart regenerative therapy - Medical Xpress - April 28th, 2024
- John Cleese is spending thousands on stem cell therapy is it really the secret to anti-ageing? - Yahoo Lifestyle Australia - April 28th, 2024
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
Recent Comments